PatientZero — AI Diagnostic Solutions

Complex Case Zero

male

1980-01-01Since Mar 2026Last seen Sep 28, 2026

COMPREHENSIVE PATIENT CASE REPORT Confidential Medical Document — For Provider Use UPDATE — September 27, 2026 New since the March 2026 version of this report (full values in sections 7d–7g and 8): • Sep 8, 2026 Labcorp panels: PTH, Intact 18 pg/mL (15–65) with calcium 9.9 mg/dL; ANA Direct negative; ANCA, RF, anti-CCP, HLA-B27 negative; C3/C4 normal. Flagged: glucose 104 (H), LDL 125 (H), ApoB 94 (H), estradiol 6.6 (L). • Jun 2026 urine mycotoxins: ochratoxin A, aflatoxin group, and macrocyclic trichothecenes reported PRESENT. • Jun 2026 urine toxic metals: bismuth and thallium above reference. • Jun 2026 stool metagenomics: summary score 50/100 (lowest 20%); Enterobacteriaceae 11.4%, E. coli 10.7%, C. difficile detected, Bifidobacterium and Akkermansia 0%. • 3X4 genetic report: APOE E3/E4, GSTM1 deletion, TCN2 GG, MTHFR 677 CT + 1298 AC, NAT2 slow. • Sep 17, 2026 CBCT acquired (689 axial slices). • Apr 2, 2026 Emory bilateral maxillary bone biopsy: pathologist reads "reactive/reparative changes… argue against a diagnosis of osteomyelitis"; bone culture NO GROWTH. Obtained while on antibiotics — doxycycline ~4 weeks before, switched to amoxicillin-clavulanate (Augmentin) around the procedure (patient-reported). Full results and antibiotic context in 7h. Values that differ from earlier reports are listed side by side in 7g; the working diagnoses in section 9 are unchanged from the March version. 1. PATIENT DEMOGRAPHICS Name: Complex Case Zero (de-identified record) DOB: 01/01/1980 | Sex: Male Contact and location: withheld PCP: Dr. Iskra Magick Myers Current Surgeon: Dr. John Palmer, Palmer Distinctive Dentistry (IAOMT Mastership) 2. CHIEF COMPLAINT Progressive bilateral maxillary bone disease of 18+ months duration. Chronic pain, bone loss, non-healing surgical sites, 4 molar extractions, multiple failed antibiotic courses, and systemic symptoms including fatigue, nausea, sleep disruption, bilateral foot edema with erythromelalgia pattern, neuropathy, and local anesthesia resistance. Self-ordered labs on March 2, 2026 revealed normocalcemic primary hyperparathyroidism and positive ANA with nucleolar pattern (systemic sclerosis association). 3. RELEVANT MEDICAL HISTORY 3a. General Medical History • Sobriety: 15+ years sober. No alcohol or recreational drugs. Critical: opioids contraindicated per patient preference and history. • ADHD: Diagnosed, treated with dextroamphetamine sulfate (daily). • Chronic depersonalization: Since age 16. Described as living with "one foot in each world." • Neuropathy: Bilateral feet — spots that do not respond normally to touch. Large tendons tighten intermittently causing gait difficulty. Patient uses tuning fork vibration therapy for symptomatic relief. • Erythromelalgia pattern: Feet turn red and swell in heat (hot shower steam, prolonged standing in warm environments). Consistent with small vessel vasomotor dysfunction. • Previous vascular crisis: Present at time of La Cantera Dental procedures (Feb 2025). Nature not fully documented. • Ancestry: Italian, Ashkenazi, Cherokee. Relevant for autoimmune predisposition (Ashkenazi — elevated scleroderma risk). 3b. Dental/Surgical History (Chronological) DATE PROVIDER LOCATION PROCEDURE / FINDINGS Feb 21, 2025 La Cantera Dental San Antonio, TX Full-mouth SRP + 8 composite fillings (#3, #10, #14, #15, #29, #30, #31 +1) + RCT redo on #10 with Core-X build-up + gingival irrigation + desensitizer x8. Single session. No clinical notes or imaging documenting caries. May 2025 Endodontist San Antonio, TX Root canal on #3. May 26, 2025 Zam Dental / Dr. Zamora San Antonio, TX Crown #3. Crown oversized. Adjacent teeth #2 and #4 ground down. Crown cemented by student. Zamora pulled on crown, stated "I'm done," left room. $3,500 cash — two insurances refused. Jun 2025 Dr. Robert Naples, OFS Round Rock, TX Extracted #3. Found necrotic bone. Placed cadaver bone graft. Graft never integrated. MRI 9 months later: persistent marrow edema at graft site. Jul-Sep 2025 Dr. Kevin Chang / Transcend Round Rock, TX Multiple visits. CBCT obtained. Vertical root fracture #14 not identified for 5 months. Aug-Sep 2025 Multiple biological dentists San Antonio, TX Laser therapy, ozone injections, IV ozone therapy. Infection persisted. Sep 2025 Olmos Dental San Antonio, TX Ozone injection. Diagnosed TMJ and nervous system overload. Sep 2025 Vaughn Endo TX 2-hour evaluation. Stated could attempt RCT #14 but cannot guarantee no extraction. Stated #15 needs crown (contradicting Olmos finding). Oct 2025 Dr. Nunnally, Nunnally Freeman Owens Marble Falls, TX Extracted #15. Intraoperative findings: "mush, dead blood vessels, tissue your body wanted to push out." No biopsy obtained. No culture obtained. No bone graft placed (per patient request). #15 site has NOT healed at 5 months post-extraction. Nov 2025 Capital ENT & Sinus Center Lakeway, TX ENT evaluation for sinus burning and bitter drainage. Endoscopy performed. Oroantral communication suspected. Nov 2025 Governor-appointed Periodontist TX Stated: "You do NOT have periodontal disease." Fall 2025 Multiple providers (6+) NC Anders Dental: refused to see patient. Chicory Family: "I can't help you." Asheville MaxFax: delayed 30 days for being 20 min late. Southern Dental: diagnosed trigeminal neuralgia. Embark Dental: agreed to extract, reversed, discharged. Fall 2025 Atrium Health / Mission Imaging NC Nuclear bone scan (Tc-99m): Active bilateral maxillary uptake. Focal throat uptake (possible parathyroid adenoma). Radiologist read: TMD, nothing abnormal. Dec 2025 Prisma Greenville, Pelham MC, Bon Secours ERs SC 3 ERs in 48 hours. Pelham labs: Monocytes 10.5%, Basophils 1.2%, PLT 397, MPV 7.0 L. Patient requested CRP/ESR — refused. All discharged without treatment. Dec 2025 Emory University Hospital ER Atlanta, GA Morphine administered without informed consent to 15+ year sober patient. Clindamycin prescribed despite prior neurotoxicity concern. OMFS available in-house, not consulted. 24 hrs vomiting, missed antibiotic doses. Jan 2026 Mission Imaging NC Nuclear bone scan obtained (referenced above). Feb 2026 Angel Medical Center ER Franklin, NC WBC 12.0 — active infection. Discharged without antibiotics. Feb 2026 Concierge Internist SC Multiple visits. Did not order PTH or ANA. Feb 2026 CBCT (self-obtained) NC/SC Patient reviewed own imaging. Irregular bone density patterns anterior maxilla consistent with necrotic/ischemic bone changes. Heterogeneous marrow pattern bilaterally. ~Feb 2026 Periodontal maintenance cleaning SC Post-cleaning, patient swished Listerine. Thick white biofilm/bone debris expelled. Fistula at #15 opened. #14 began to throb. Alkaline carbonation sensation at #14 — consistent with calcium carbonate effervescence from actively dissolving bone. Mar 2, 2026 PATIENT SELF-ORDERED Quest Diagnostics Self-ordered: PTH Intact, Calcium, Vitamin D 25-OH, ANA Cascade with reflex, Autoimmune/Inflammation Marker Panel, Osteoporosis Panel, RF, CCP, ESR, CRP. First provider to order PTH or ANA in 18 months. Mar 5, 2026 Dr. Palmer Greenville, SC Left side osseous NICO debridement #14-#15. #14 extracted. Sinus lift. PRF plug placed. Right side NOT completed — local anesthesia ineffective, patient in pain. Surgeon terminated. Hard mass (involucrum) above #14 site not addressed. #13 palatal swelling not addressed. Tooth scraping collected by patient into DNA Connections PCR kit, refrigerated. Apr 2, 2026 Emory University Hospital (OMFS clinic / surgical pathology) Atlanta, GA Bilateral maxillary bone biopsy with anaerobic + aerobic culture. Taken after ~4 weeks of doxycycline; antibiotic switched to amoxicillin-clavulanate (Augmentin) around the procedure (patient-reported). Pathology: reactive/reparative bone, "argue against a diagnosis of osteomyelitis." Culture: no growth. See 7h. 4. ACTIVE SYMPTOMS — CURRENT 4a. Oral/Maxillofacial • Left maxilla: Post-surgical. Oozing (pinkish, not active bleeding). Stitches at #14 extraction and posterior to #15. Deep pressure previously at #14 now RESOLVED post-surgery. Palatal swelling at #13 NOT resolved — tender, firm, on opposite side of surgical incision. • Right maxilla (#2): Active. Twitching/vibrating sensation under gums. Internal bubbling identical to pre-extraction #14. Interpreted as active bone dissolution or gas-producing anaerobic bacterial activity. • Hard mass above #14 site: Palpable, solid, root-shaped indentation. Tooth is extracted (in patient's possession). Mass is consistent with involucrum — reactive bone formed around chronic osteomyelitis. • #15 socket: Empty, soft, mush-like. Non-healing at 5 months. Consistent with avascular bone bed. • Lower jaw (#29, #30, #31): Palpable bone lumps under gums at all three La Cantera filling sites. • Alkaline taste: Intermittent. Consistent with calcium phosphate leaching from dissolving bone. • Sinus: Left sinus communication addressed by Palmer today (sinus lift/plug). Right sinus — bitter drainage, burning, previously documented oroantral communication suspected. 4b. Systemic • Bilateral foot edema: Feet swell and turn red in heat (hot shower, prolonged standing). Pattern consistent with erythromelalgia / small vessel vasomotor dysfunction. Spots on feet that do not respond normally to touch (small fiber neuropathy). Large foot tendons tighten intermittently. • Nausea: Intermittent. Correlates with sinus drainage into stomach and with elevated calcium (hypercalcemia symptom). • Fatigue: Chronic. Consistent with both hyperparathyroidism and autoimmune disease. • Sleep disruption: Chronic. Medication interaction (magnesium malate + gabapentin) exacerbates — magnesium competes at same voltage-gated calcium channels gabapentin modulates. • Vasodilation episodes: "Niacin flush" sensation without taking niacin. Consistent with histamine release from active bone remodeling / osteoclast activity. • Facial swelling: Fluctuates. Recently noted to be less swollen by provider (possible inflammation reduction on doxycycline). Interpreted by patient as bone/tissue edema from vascular compromise. • Local anesthesia resistance: Documented failure during surgery March 5, 2026. Mechanism: elevated serum calcium stabilizes sodium channels, antagonizing lidocaine/articaine. 5. CURRENT MEDICATIONS 5a. Prescription Medications MEDICATION DOSE FREQUENCY NOTES Dextroamphetamine sulfate Per Rx Daily ADHD. Held morning of surgery, resume Day 2. Long-term (5+ years). Gabapentin Per Rx Daily Neuropathic pain. INTERACTION: Magnesium malate competes at same voltage-gated calcium channels. Must separate by 2+ hours. INTERACTION: Elevated calcium from hyperparathyroidism affects channel function. Long-term gabapentin associated with decreased BMD — accelerant in context of active PTH-driven bone resorption. Clonidine Per Rx Daily Blood pressure / sleep. Clindamycin 500 mg 3x/day (TID) Current course: Day 9 of current cycle. ONE DAY SUPPLY REMAINING as of March 5. CRITICAL: Does not cover gram-negatives. Previous Augmentin courses may have selected for resistant gram-negative organisms. No culture-directed antibiotic therapy has ever been attempted. Zofran (ondansetron) Per Rx PRN nausea As needed. Toradol (ketorolac) Per Rx PRN pain Days 1-5 Post-surgical pain management. 5b. Current Supplement Protocol SUPPLEMENT DOSE TIMING PURPOSE / NOTES Vitamin D3 10,000 IU Daily Despite 10K daily, 25-OH level only 37 ng/mL (barely adequate). Body is burning through D3 for calcium homeostasis. Target: 60-80 ng/mL. Vitamin K2 (D3/K2 drops) Per label Daily Activates osteocalcin (drives calcium INTO bone) and matrix GLA protein (keeps calcium OUT of arteries). Despite supplementation, bones still dissolving — PTH overpowering K2 signal. Bone Restore Elite 4 caps Daily (lunch) Calcium, magnesium, minerals for bone support. MUST separate from Clindamycin by 3-4 hours — calcium blocks antibiotic absorption. Post-op: restart Day 2-3. Magnesium Malate 3 tabs Daily INTERACTION: Competes with gabapentin at voltage-gated calcium channels. Separate by 2+ hours. INTERACTION: Shifts Ca:Mg ratio — can trigger sweating, restless legs, excitatory rebound in context of hyperparathyroidism. PerfectAmino Per label Morning (empty stomach) Essential amino acids for tissue repair. No bleeding or interaction risk. Colostrum Per label Morning (empty stomach) Immune support, gut repair. Sodium Ascorbate (Vitamin C) Per label 2x/day Antioxidant, collagen synthesis, immune support. Arginine Citrulline Per label Afternoon (Day 4+) Nitric oxide production, blood flow to bone. POST-OP: Hold Days 1-3 (vasodilator, increases bleeding risk). Elderberry Per label Dinner Immune support. Cell Salts Per label 2x/day Mineral support. DentaMedica Per label Daily Dental-specific nutritional support. Gut Spore + Gut Connection Per label Daily Probiotic / gut integrity. Relevant given multiple antibiotic courses. Lymph Tonic Per label Afternoon Lymphatic drainage support. Buffalo Bone Tea Per label Day 3+ Bone-building minerals, traditional preparation. Burbur-Pinella Drops 2x/day tapering Detoxification support. Manuka Honey Topical + oral Daily (Day 4+ on sites) Antimicrobial wound application on surgical ridges. Also taken orally. L-Theanine Per label Bedtime Calming, sleep support. Passion Flower Tea Tea Bedtime Sleep support. Celtic Sea Salt Per taste In water, food Mineral replenishment, electrolyte balance. Bone Broth Cup Daily Collagen, minerals, gut repair. 5c. Supplements Currently HELD (Post-Surgical) SUPPLEMENT RESTART REASON FOR HOLD CuraMed Curcumin Week 3 Blood thinning properties, bleeding risk post-surgery. Vitamin E 400 IU Week 2 Blood thinning. NAC Week 3 (half dose) Resume low and build up. Niacin Week 2 Vasodilator — increases bleeding risk. CBD Softgels Day 4 Mild blood thinning. Nattokinase / Serrapeptase Week 3 Fibrinolytic — significant bleeding risk. G.I. Detox Binder Week 2 Must be 2 hours from all other supplements/meds. 5d. Topical / Therapeutic Modalities • Red/Pink light therapy wand: Applied externally to cheeks over surgical areas. 2-3 minutes per side. Starting Day 5+. • Tuning forks: Used on feet for neuropathy symptom relief. Gentle near jaw from Day 6+. • Magnesium lotion: Topical, nightly. • XyliSwish: Xylitol-based oral rinse. NOT until Day 7+. No swishing — gentle rinse only. • Baking soda rinse: Passive soak (not swishing) starting Day 2. Gravity drain. • Ancient Magnetic Clay + bath salts: Detox baths, weekly from Day 6+. • Methylene blue: Used diagnostically by patient to identify cracks/pathology on extracted teeth. NOT for oral application on surgical sites. • DMSO: In emergency kit. Not currently in active use. 6. FAILED ANTIBIOTIC COURSES The following antibiotics have been administered over 18 months without culture-directed targeting. No bone culture or pathogen identification has ever been performed until the patient's self-collected DNA Connections PCR sample on March 5, 2026. ANTIBIOTIC COVERAGE OUTCOME Augmentin (multiple courses) Gram+, gram-, anaerobes GI destruction (nausea, vomiting). May have selected for resistant organisms. Temporary symptom relief only. Clindamycin (multiple courses) Gram+, anaerobes. NO gram-negative coverage. Current course Day 9. Does NOT cover gram-negatives that Augmentin may have selected for. Gap in coverage. Doxycycline Broad spectrum + bone penetration Some stabilization noted. Bone penetration advantageous. Interacts with calcium supplements (separate by 3-4 hrs). Others (unspecified) Various 6+ total courses. All empiric. None culture-directed. All failed to resolve underlying bone infection. CRITICAL: No provider has ever obtained a bone culture or tissue culture for sensitivity testing. Treatment has been empiric for 18 months. 7. LABORATORY DATA 7a. Calcium Trend Over Time DATE CALCIUM REF RANGE NOTES Aug 2, 2025 9.1 8.6-10.3 Baseline. ~Sep 2025 9.8 8.6-10.3 Rising. ~Oct 2025 9.0 8.6-10.3 Transient dip. ~Nov 2025 10.1 8.6-10.3 At upper limit. ~Dec 2025 10.0 8.6-10.3 Sustained high. Mar 2, 2026 9.9 8.6-10.3 High-normal. With PTH 58, this = inappropriately non-suppressed PTH. Normocalcemic primary hyperparathyroidism. Trend: Calcium persistently at or near upper reference limit despite 10,000 IU Vitamin D + K2 + Bone Restore supplementation. No provider ordered PTH until patient self-ordered. 7b. March 2, 2026 — Self-Ordered Panel (Quest Diagnostics) TEST VALUE RANGE INTERPRETATION PTH, Intact 58 pg/mL 16-77 Upper half of range. Inappropriately elevated for calcium of 9.9. Should be suppressing. Indicates autonomous parathyroid function. Calcium 9.9 mg/dL 8.6-10.3 High-normal. Paired with PTH 58 = normocalcemic primary hyperparathyroidism. Vitamin D, 25-OH 37 ng/mL 30-100 Barely adequate despite 10,000 IU/day. Body consuming D for calcium homeostasis. Rules out secondary hyperparathyroidism from D deficiency — this is primary. ANA Screen, IFA POSITIVE NEGATIVE Antinuclear antibodies detected. ANA Titer 1:40 H <1:40 Neg Low titer. However, nucleolar pattern is clinically significant regardless of titer. ANA Pattern Nuclear, Nucleolar N/A AC-8,9,10 Nucleolar. Associated with: systemic sclerosis (scleroderma), scleroderma/polymyositis overlap, Sjogren's syndrome. Scleroderma causes small vessel fibrosis/constriction — explains ischemic bone disease, non-healing surgical sites, erythromelalgia, local anesthesia resistance. Rheumatoid Factor <10 IU/mL <14 Negative. RA ruled out. CCP Ab (IgG) <16 Units <20 Neg Negative. RA confirmed ruled out. ESR 2 mm/h <=15 Normal. Does NOT rule out scleroderma (fibrotic/vascular, not primarily inflammatory) or chronic osteomyelitis (walled off in avascular bone). CRP <3.0 mg/L <8.0 Normal. Same caveat as ESR. MCV Ab IN PROGRESS Pending. 14-3-3 Eta Protein IN PROGRESS Pending. Marker for early joint destruction. DNA (DS) Ab IN PROGRESS Pending. If positive = lupus. SM Ab IN PROGRESS Pending. If positive = lupus. SM/RNP Ab IN PROGRESS Pending. If positive = mixed connective tissue disease. RNP Ab IN PROGRESS Pending. Chromatin (Nucleosomal) Ab IN PROGRESS Pending. If positive = lupus. 7c. Prior Lab Results (Selected) Nov 19, 2025 (Dr. Pico, Quest): CBC normal — WBC 7.3, RBC 5.24, Hgb 15.0, Hct 46.5, Platelets 394 (approaching upper limit). Sep 2025 (Dr. Pico): CMP normal. CRP 1, ESR 2. ANA panel: all negative. Thyroid normal. Autoimmune ruled out (INCORRECTLY — did not test for scleroderma-specific markers or nucleolar ANA pattern). Dec 2025 (Pelham MC ER): Monocytes 10.5% (H), Basophils 1.2% (H), PLT 397, MPV 7.0 L. Patient requested CRP/ESR — refused by ER. Platelet trend: Rising — 394 (Nov) → 397 (Dec). High platelets + low MPV = reactive thrombocytosis consistent with chronic inflammation and/or bone marrow stimulation from hyperparathyroidism (PTH acts directly on marrow within resorbing bone). Nuclear bone scan (Jan 2026, Tc-99m): Active bilateral maxillary uptake. Focal throat uptake. Radiologist read: TMD. Clinical significance: bilateral maxillary pathology + possible parathyroid adenoma. 7d. September 8, 2026 — Labcorp Comprehensive Panel (fasting) TEST VALUE REFERENCE FLAG TSH 2.170 uIU/mL 0.450–4.500 Free T3 3.4 pg/mL 2.0–4.4 Free T4 1.26 ng/dL 0.82–1.77 WBC 6.9 x10E3/uL 3.4–10.8 RBC 5.12 x10E6/uL 4.14–5.80 Hemoglobin 14.8 g/dL 13.0–17.7 Hematocrit 44.1 % 37.5–51.0 MCV / MCH / MCHC 86 fL / 28.9 pg / 33.6 g/dL 79–97 / 26.6–33.0 / 31.5–35.7 RDW 13.9 % 11.6–15.4 Platelets 392 x10E3/uL 150–450 Differential Neut 62% · Lymph 28% · Mono 8% · Eos 1% · Baso 1% · Immature gran 0% (absolute counts all within range) Glucose 104 mg/dL 70–99 HIGH BUN / Creatinine 11 / 0.98 mg/dL 6–24 / 0.76–1.27 eGFR 98 >59 Sodium / Potassium / Chloride / CO2 139 / 5.1 / 102 / 21 mmol/L 134–144 / 3.5–5.2 / 96–106 / 20–29 Calcium 9.9 mg/dL 8.7–10.2 Protein / Albumin / Globulin 7.2 / 4.6 / 2.6 g/dL 6.0–8.5 / 4.1–5.1 / 1.5–4.5 Bilirubin, total 0.5 mg/dL 0.0–1.2 Alkaline Phosphatase 62 IU/L 47–123 AST / ALT 16 / 14 IU/L 0–40 / 0–44 Cholesterol, total 193 mg/dL 100–199 Triglycerides 41 mg/dL 0–149 HDL 61 mg/dL >39 LDL (NIH calc) 125 mg/dL 0–99 HIGH Apolipoprotein A-1 167 mg/dL 101–178 Apolipoprotein B 94 mg/dL <90 HIGH ApoB/A-1 ratio 0.6 0.0–0.7 Hemoglobin A1c 5.4 % 4.8–5.6 Iron / TIBC / Saturation 94 ug/dL / 332 ug/dL / 28 % 38–169 / 250–450 / 15–55 Ferritin 43 ng/mL 30–400 Transferrin 272 mg/dL 177–329 DHEA-Sulfate 157.0 ug/dL 102.6–416.3 Testosterone 607 ng/dL 264–916 Estradiol 6.6 pg/mL 7.6–42.6 LOW Vitamin A 41.7 ug/dL 20.1–62.0 Vitamin D, 25-OH 43.1 ng/mL 30.0–100.0 hs-CRP 0.66 mg/L 0.00–3.00 Homocysteine 14.2 umol/L 0.0–14.5 (not flagged; upper edge) Uric Acid 5.5 mg/dL 3.8–8.4 LDH 183 IU/L 121–224 (specimen hemolyzed per lab) GGT 19 IU/L 0–65 ESR 2 mm/hr 0–15 Ceruloplasmin 21.0 mg/dL 16.0–31.0 Copper / Zinc 80 / 80 ug/dL 66–121 / 44–115 Magnesium, RBC 5.5 mg/dL 3.7–7.0 7e. September 8, 2026 — Labcorp Autoimmune / Complement / PTH Panel TEST VALUE REFERENCE PTH, Intact 18 pg/mL 15–65 Phosphorus 3.7 mg/dL 2.8–4.1 ANA Direct (multiplex, reflex 5) Negative Negative ANCA by IFA Negative Negative Anti-MPO / Anti-PR3 <20 / <20 Units <20 Rheumatoid Factor <10.0 IU/mL <14.0 Anti-CCP IgG/IgA 3 units 0–19 HLA-B27 Negative Complement C3 / C4 121 / 19 mg/dL 82–167 / 12–38 7f. June 2026 — Functional / Environmental Testing Urine mycotoxins (collected Jun 1, 2026): • Ochratoxin A 3.383 ppb — PRESENT (present ≥2) • Aflatoxin group (B1/B2/G1/G2) 1.455 ppb — PRESENT (present ≥1) • Macrocyclic trichothecene group 0.150 ppb — PRESENT (present ≥0.09) • Gliotoxin derivative <0.000 — not present; Zearalenone 0.372 — not present (present ≥0.7) Urine toxic metals, ICP-MS, creatinine-corrected (collected Jun 3, 2026; creatinine 82.5 mg/dL): • Bismuth 1.6 µg/g creat — HIGH (<0.8) • Thallium 0.47 µg/g creat — HIGH (<0.4) • Within reference: aluminum 8.9, antimony 0.072, arsenic 9.0, barium 2.9, cadmium 0.10, cesium 6.5, gadolinium 0.37, lead 0.33, mercury 0.072, nickel 2.6, palladium 0.14, tin 0.31, tungsten 0.087, uranium 0.009; beryllium, platinum, tellurium, thorium below detection. Stool shotgun metagenomics (collected Jun 1, 2026): • Microbiome summary score 50/100 (lowest 20%; "major imbalances") • Needs support: Enterobacteriaceae 11.374%, Escherichia coli 10.693%, E. flexneri 0.380%, E. dysenteriae 0.049%, Klebsiella pneumoniae 0.008%, Clostridioides difficile 0.024%, Bifidobacterium 0%, Akkermansia 0%, Ruminococcus gnavus 1.332% • Gut barrier indices: Hexa-LPS 96.0, mucus degradation 89.4, hydrogen sulfide 96.0 (all "needs support"); oxygen exposure 0.09 • Antibiotic resistance signature: abundance 0.17, richness 0.22 (needs support) • Microbiome age 73.8 years; beta-glucuronidase capacity 1940; acetate 280 rpkm (low); propionate 229 rpkm • Within range or better: butyrate 513 rpkm, species richness 254, Faecalibacterium 4.337%, oral microbes 0%, no parasites or fungi detected Genetic report (3X4 Blueprint v4.0.2): • Highest-impact genes: APOE E3/E4, GSTM1 deletion, TCN2 776 GG, ACTN3 RR • Other notable: MTHFR 677 CT and 1298 AC, NAT2 slow acetylator, COMT Val158Met GG, MNSOD Val16Ala TT, HLA-DQ2.5/DQ8X • Pathways rated VERY HIGH impact: oxidative stress, detoxification, collagen & joints, memory & brain health, adipogenesis, energy expenditure, weight gain/loss resistance, injury, recovery, vitamin B12 7g. Values That Differ From Earlier Reports (side by side, no interpretation) • Osteomyelitis: section 9 item 1 lists chronic osteomyelitis as confirmed by intraoperative findings (Oct 2025, Mar 2026). Apr 2, 2026 bone biopsy histology: "argue against a diagnosis of osteomyelitis"; culture no growth. Both samples obtained on antibiotic therapy (see 7h). • PTH, Intact: 58 pg/mL (Mar 2, 2026, Quest; ref 16–77) → 18 pg/mL (Sep 8, 2026, Labcorp; ref 15–65). Calcium 9.9 mg/dL on both dates. • ANA: POSITIVE, titer 1:40, nuclear/nucleolar pattern (Mar 2, 2026, Quest IFA) → ANA Direct NEGATIVE (Sep 8, 2026, Labcorp multiplex). Different assay methods. • Vitamin D, 25-OH: 37 ng/mL (Mar 2, 2026) → 43.1 ng/mL (Sep 8, 2026). • Platelets: 394–397 (Nov–Dec 2025) → 392 (Sep 8, 2026). ESR 2 on both. 7h. April 2, 2026 — Bilateral Maxillary Bone Biopsy, Emory University Hospital ANTIBIOTIC EXPOSURE AT TIME OF SAMPLING (patient-reported): • Doxycycline for ~4 weeks leading up to the biopsy. • Switched to amoxicillin-clavulanate (Augmentin) around the time of the procedure. • Both culture and histology were therefore obtained on active antibiotic therapy. Prior antibiotic exposure is a recognized cause of false-negative bone cultures. SURGICAL PATHOLOGY (signed Apr 8, 2026; reviewed at Emory Head & Neck Pathology Consensus Conference, uniform agreement) A. Right maxillary bone: • Lamellar bone with remodeling; some trabeculae surrounded by reactive woven bone. • Small regions of NON-VIABLE lamellar bone, some surrounded by viable woven bone formation. • Two sub-millimeter foci of polarizable foreign material in fibrous stroma, no surrounding inflammation (pathologist: may relate to prior local treatment, e.g. root canal therapy). • Sparse/mild background inflammation ("not unexpected in view of dental extraction history"). No organisms or neoplasm. B. Left maxillary bone: • Lamellar and woven bone with remodeling; predominantly woven bone layered on small foci of viable-appearing lamellar bone. • Sparse/mild inflammation. No organisms, foreign material, or neoplasm. Pathologist's overall statement: "the microscopic findings are most consistent with reactive/reparative changes, and argue against a diagnosis of osteomyelitis." Special stains: CK AE1/3 negative in cells of interest (A and B); GMS fungal stain negative (A and B). Lab disclaimer: IHC not validated on decalcified tissue — possible false negativity. Specimens: multiple bone fragments, right 0.1–0.3 cm, left 0.1–0.5 cm; decalcified before sectioning. ANAEROBIC + AEROBIC CULTURE WITH GRAM STAIN (biopsy bone) • Culture: NO GROWTH • Gram stain: rare Gram-positive cocci (flagged abnormal); few WBCs (flagged abnormal); no epithelial cells (flagged abnormal) Comparison with the Mar 2, 2026 DNA ConneXions PCR (bloody saliva from extraction site, collected before this antibiotic course): 15 organisms detected, 13 in the serious-risk band. PCR detects DNA and does not require viable organisms; culture requires live organisms. 8. IMAGING HISTORY • Multiple dental X-rays: Various providers, 2025. No specific findings documented by most. • CBCT (Transcend Dental, Jul-Sep 2025): Obtained. VRF #14 missed for 5 months. • CBCT (Feb 2026, self-reviewed): Irregular bone density patterns in anterior maxilla anterior to tooth roots. Heterogeneous marrow pattern bilaterally. Patient interpretation: necrotic/ischemic bone changes. No formal radiology read consistent with clinical findings. • MRI (referenced, ~late 2025): Persistent marrow edema at #3 graft site (9 months post-graft). Mild bilateral marrow edema. Read as unremarkable by radiologist. • Nuclear bone scan (Jan 2026, Mission Imaging): Tc-99m. Active bilateral maxillary uptake. Focal throat uptake. Read as TMD. Clinical significance: active bone metabolism bilaterally + possible parathyroid adenoma at throat. • ENT endoscopy (Nov 2025): Images obtained. Oroantral communication suspected. • CBCT (Sep 17, 2026): Planmeca ProMax, 689 axial slices, 804×804, 0.25 mm isotropic, JPEG 2000 lossless. Loaded into the viewer for this record. No formal radiology read on file. NEEDED: Post-operative CBCT to evaluate #13, #2, involucrum at #14 site, and extent of remaining disease. Gadolinium-contrast MRI to differentiate living edematous bone from dead avascular bone. 9. WORKING DIAGNOSES 1. Chronic osteomyelitis of maxilla with involucrum formation — Confirmed by intraoperative findings (Nunnally: necrotic marrow, dead vasculature; Palmer: NICO debridement). 18+ months duration. Non-healing despite multiple antibiotic courses (none culture-directed). Bilateral distribution. 2. Normocalcemic primary hyperparathyroidism — PTH 58 with calcium 9.9. PTH failing to suppress at upper limit calcium. Driving osteoclast-mediated bone resorption systemically. MECHANISM 1 of bone destruction: chemical dissolution. 3. Positive ANA, nucleolar pattern (AC-8,9,10) — systemic sclerosis evaluation needed — Associated with scleroderma, which causes small vessel fibrosis and vascular constriction. MECHANISM 2 of bone destruction: ischemic deprivation. Explains bilateral ischemic osteonecrosis, non-healing surgical sites, erythromelalgia, small fiber neuropathy, local anesthesia resistance. 4. Iatrogenic dental injury — 8 composite fillings and RCT redo without documented justification (La Cantera). 100% failure rate. Precipitating event for cascade. 5. Small fiber neuropathy — bilateral feet — Spots with abnormal touch response. Tendon tightening. Erythromelalgia pattern. Consistent with scleroderma vascular involvement. 6. Possible oroantral communication — Sinus involvement bilateral. Addressed partially by Palmer (left side sinus lift, March 5, 2026). Right side status unknown. 7. Gabapentin-calcium-magnesium interaction — Triple interaction at voltage-gated calcium channels in context of hyperparathyroidism. Contributing to symptom burden, sleep disruption, and breakthrough neuropathic pain. 10. OUTSTANDING DIAGNOSTIC NEEDS IMMEDIATE: • DNA Connections PCR pathogen panel: Sample collected March 5, 2026 from extracted tooth #14 root scrapings. First-ever pathogen identification. Will enable culture-directed antibiotic therapy. • Pending antibody results: Anti-dsDNA, SM, SM/RNP, RNP, Chromatin, MCV, 14-3-3 Eta. Will confirm autoimmune subtype. • Post-operative CBCT: Evaluate surgical site, #13 pathology, #2 status, involucrum remnant, extent of remaining disease. • Clindamycin continuation/switch: Only 1 day supply remaining. Cannot lapse with open surgical wound and active bilateral bone infection. SHORT-TERM (1-4 WEEKS): • Endocrinology referral: Sestamibi scan to locate parathyroid adenoma. Determine if surgical parathyroidectomy indicated vs. monitoring. • Rheumatology referral: Scleroderma workup — nailfold capillaroscopy, Scl-70 antibody, anti-centromere antibody, skin assessment, pulmonary function baseline. • Gadolinium-contrast MRI of maxilla: Differentiate living edematous bone (lights up) from dead avascular bone (stays dark). Determines which areas need surgical debridement vs. which may respond to medical management. • Second side surgery (#2, #13 evaluation): With proper anesthesia (IV sedation or general — NOT local infiltration alone given calcium level). Culture tissue intraoperatively. LONG-TERM: • Pentoxifylline/tocopherol/clodronate (PENTOCLO) protocol evaluation: For revascularization of ischemic bone. Requires endocrinology and rheumatology input. • Hyperbaric oxygen therapy evaluation: For non-healing bone in context of vascular compromise. • Bone density scan (DEXA): Baseline assessment given hyperparathyroidism + long-term gabapentin + autoimmune bone involvement. • Gabapentin alternatives: Evaluate non-calcium-channel medications for neuropathic pain given hyperparathyroidism interaction. • Vitamin D dose optimization: Current 10K IU achieving only 37 ng/mL. Target 60-80 ng/mL. May need higher dose or different formulation. 11. PATIENT ADVOCACY NOTE This patient has demonstrated exceptional self-advocacy, diagnostic acumen, and persistence in the face of systematic medical failure. He identified his own calcium trend, ordered his own PTH and ANA panels, collected his own tissue sample for PCR testing, and managed his own complex supplement protocol targeting bone regeneration and vascular support. He has consulted 35+ providers across 4 states over 18 months. He has spent $40,000+ out of pocket. He has lost 4 chewing molars. He has endured 6+ failed antibiotic courses, a failed bone graft, multiple ER visits, and repeated abandonment by providers. He has been misdiagnosed with TMJ, TMD, trigeminal neuralgia, nervous system overload, and phantom pain. His nuclear bone scan showing bilateral active pathology was dismissed. His requests for specific labs were refused. He diagnosed himself. Any provider reviewing this case should understand: this patient knows his body, has done extensive research, and has been correct about his own pathology at every turn. Clinical humility and genuine collaboration are requested.

One Patient. Every Perspective. Data Decides.

Patients (1)

Complex Case Zero

Coming Soon

MyChart / Epic FHIR Integration

Multi-Provider Record Aggregation

SMART on FHIR Apps

PDF Consent with E-Signature

Secure Messaging

Wearable Data Integration